SCHEMBL6316935

SCHEMBL6316935

CCOC(=O)CN1C(=O)C(=NOCc2ccccc2)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.43
ALDH1A1 P00352 6/20 0.41
MAPT P10636 5/20 0.41
HTT P42858 2/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
LMNA P02545 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 2/20 0.40
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39
POLB P06746 1/20 0.37
PTPN1 P18031 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PIN1 Q13526 1/20 0.36
PIN4 Q9Y237 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316929 1.00 PPARG (0.43) PPARGALDH1A1MAPTHTTHSD17B10
SCHEMBL6317571 0.86 ALDH1A1 (0.49) PPARGALDH1A1MAPTHTTKMT2A
SCHEMBL6317569 0.86 ALDH1A1 (0.49) PPARGALDH1A1MAPTHTTKMT2A
SCHEMBL6316214 0.85 ALDH1A1 (0.44) PPARGALDH1A1MAPTHTTHSD17B10
SCHEMBL6317019 0.84 CASP1 (0.47) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL6322889 0.83 PPARG (0.46) PPARGALDH1A1MAPTHTTHSD17B10
SCHEMBL6322891 0.83 PPARG (0.46) PPARGALDH1A1MAPTHTTHSD17B10
SCHEMBL6316609 0.81 MAPT (0.40) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL6316612 0.81 MAPT (0.40) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL9174935 0.79 ALDH1A1 (0.56) PPARGALDH1A1MAPTHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969729-B2 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2005-11-29 US claimed
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S 2003-06-19 US claimed
JP-2002531498-A 2002-09-24 JP claimed
US-20020016354-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2002-02-07 US claimed
EP-1135123-A1 USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS NEUROSEARCH A/S (DK) 2001-09-26 EP claimed
WO-2000033834-A1 USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS NEUROSEARCH A/S (DK) 2000-06-15 WO claimed
US-10808062-B2 Polyol composition and thermosetting resin KANEKA CORPORATION (JP) 2020-10-20 US disclosed
EP-3421541-A1 POLYOL COMPOSITION AND THERMOSETTING RESIN Kaneka Corporation (JP) 2019-01-02 EP disclosed
US-20180362694-A1 POLYOL COMPOSITION AND THERMOSETTING RESIN KANEKA CORPORATION (JP) 2018-12-20 US disclosed
US-6969729-B2 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2005-11-29 US disclosed
US-20050182225-A1 Curable resin composition KONISHI CO. LTD (JP) 2005-08-18 US disclosed
EP-1514903-A1 CURABLE RESIN COMPOSITION Konishi Co., Ltd. (JP) 2005-03-16 EP disclosed
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S 2003-06-19 US disclosed
US-20020016354-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2002-02-07 US disclosed
EP-0432648-B1 Isatine derivatives, their preparation and use NEUROSEARCH AS (DK) 1995-08-02 EP disclosed
US-5198461-A Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1993-03-30 US disclosed
EP-0432648-A2 Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1991-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents KCNN3, KCNJ2, KCND2 PPARG 3974/4885ALDH1A1 3865/4885MAPT 1939/4885
US-20020016354-A1 Use of isatin derivatives as ion channel activating agents KCNN3, KCNJ2, KCND2 PPARG 3954/4885ALDH1A1 4102/4885MAPT 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.